Clinical Trials | December 09, 2024
Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr
Aims to become India’s leading cancer testing company
Aims to become India’s leading cancer testing company
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Venus Remedies secures marketing authorization in Philippines
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
For people with relapsed or refractory diffuse large B-cell lymphoma
Reaffirms Lupin’s commitment to sustainable resource management
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Subscribe To Our Newsletter & Stay Updated
